Development and validation of a Luminex assay for detection of a predictive biomarker for PROSTVAC-VF therapy.

ABSTRACT: Cancer therapies can provide substantially improved survival in some patients while other seemingly similar patients receive little or no benefit. Strategies to identify patients likely to respond well to a given therapy could significantly improve health care outcomes by maximizing clinical benefits while reducing toxicities and adverse effects. Using a glycan microarray assay, we recently reported that pretreatment serum levels of IgM specific to blood group A trisaccharide (BG-Atri) correlate positively with overall survival of cancer patients on PROSTVAC-VF therapy. The results suggested anti-BG-Atri IgM measured prior to treatment could serve as a biomarker for identifying patients likely to benefit from PROSTVAC-VF. For continued development and clinical application of serum IgM spec

SUBMITTER: Lucas JL 

PROVIDER: S-EPMC5542629 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature